Gilli F, Marnetto F, Caldano M, Sala A, Malucchi S, Di Sapio A, Capobianco M, Bertolotto A
Centro di Riferimento Regionale Sclerosi Multipla (CReSM) and Neurobiologia Clinica, Ospedale S. Luigi Gonzaga, Regione Gonzole 10, I-10043, Orbassano, Turino, Italy.
J Neuroimmunol. 2005 Jan;158(1-2):195-203. doi: 10.1016/j.jneuroim.2004.08.006.
This study is the first to evaluate biological response to first injections of interferon-beta (IFNbeta) in patients with multiple sclerosis. MxA mRNA was measured in 96 patients receiving IFNbeta-1a (Avonex, n=32), IFNbeta-1b (Betaferon, n=19), IFNbeta-1a (Rebif) 22 microg (n=30), or IFNbeta-1a 44 microg (n=15). Patients were analysed before, 3 and 24 h after the first injection, and 12 h after the second administration. Results showed that up-regulation was evident within 3 h of IFNbeta injection, peaked 12 h after injection, and progressively declined 24 h after administration. The cumulative responses were similar after a single administration, regardless of product/dose. Moreover, data indicate that the abolition of the biological activity detected during IFNbeta therapy is due to underlying phenomena (e.g., neutralizing antibodies), because all patients were constitutively responders to IFNbeta at treatment initiation.
本研究首次评估了多发性硬化症患者首次注射干扰素-β（IFNβ）后的生物学反应。对96例接受IFNβ-1a（阿沃尼）（n = 32）、IFNβ-1b（倍泰龙）（n = 19）、22微克IFNβ-1a（利比）（n = 30）或44微克IFNβ-1a（n = 15）治疗的患者测量了MxA信使核糖核酸。在首次注射前、注射后3小时和24小时以及第二次给药后12小时对患者进行分析。结果显示，IFNβ注射后3小时内上调明显，注射后12小时达到峰值，给药后24小时逐渐下降。单次给药后的累积反应相似，与产品/剂量无关。此外，数据表明，IFNβ治疗期间检测到的生物学活性的消除是由于潜在现象（如中和抗体），因为所有患者在治疗开始时对IFNβ均为固有反应者。
